n-3 Fatty Acid Infusion and Type 2 Diabetes
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Intralipid +/- Omegaven
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Intralipid, Omegaven, fish oil, hyperinsulinemic isoglycemic clamps, C-peptide glucagon test, indirect calorimetry, F2-isoprostanes
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes defined by clinical criteria and by absence of antibodies to glutamic acid decarboxylase.
- HbA1c 5,5 - 8,5 %
- Blood pressure ≤ 170 mm Hg systolic and/or ≤ 105 mm Hg diastolic
Exclusion Criteria:
- insulin treatment
- hypertriglyceridemia (> 2,1 mmol/l TG)
- proliferative retinopathy, renal insufficiency (Se-Creatinine > 150 μmol/l)
- alcoholism, congestive heart failure or other serious diseases affecting the possibility of the subject to participate
- supplement with fish oil or marine n-3 fatty acids during the last 6 months before baseline
- Dicumarol treatment
- allergy to soya, fish or egg
- pregnancy or lactation
- smoking
Sites / Locations
- Department of Medicine, Division of Endocrinology, St. Olavs Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Intralipid with/without Omegaven
Arm Description
Lipid infusion with/without marine n-3 fatty acids
Outcomes
Primary Outcome Measures
insulin sensitivity
Secondary Outcome Measures
n-3 fatty acid distribution
insulin secretion
energy metabolism
oxidative stress
Full Information
NCT ID
NCT00829569
First Posted
January 26, 2009
Last Updated
November 3, 2011
Sponsor
St. Olavs Hospital
Collaborators
Norwegian University of Science and Technology, Norwegian Foundation for Health and Rehabilitation, Novo Nordisk A/S, Norwegian Diabetes Association
1. Study Identification
Unique Protocol Identification Number
NCT00829569
Brief Title
n-3 Fatty Acid Infusion and Type 2 Diabetes
Official Title
Effects of Marine n-3 Fatty Acid Infusion on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
November 2011
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
May 2004 (Actual)
Study Completion Date
October 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
St. Olavs Hospital
Collaborators
Norwegian University of Science and Technology, Norwegian Foundation for Health and Rehabilitation, Novo Nordisk A/S, Norwegian Diabetes Association
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this experimental study is to investigate whether an acute lipid infusion added marine n-3 fatty acids produces effects on insulin sensitivity in subjects with type 2 diabetes, when compared with an acute lipid infusion without marine n-3 fatty acids. Furthermore other effects on intermediary metabolism are tested for.
Detailed Description
Evidence indicates that n-3 fatty acids exert several beneficial effects. However, the effects of marine n-3 fatty acids on intermediary metabolism have not been completely elucidated. In a previous study of a high intake of marine n-3 fatty acids during 9 wk we demonstrated reduced insulin sensitivity and altered proportion of carbohydrate vs. fat oxidation in subjects with type 2 diabetes. These results question the use of high doses of n-3 supplements in type 2 diabetes. It is not known to what extent such effects in type 2 diabetes can be reproduced by intravenous administration of n-3 fatty acids and/or whether short term intravenous administration has other effects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Intralipid, Omegaven, fish oil, hyperinsulinemic isoglycemic clamps, C-peptide glucagon test, indirect calorimetry, F2-isoprostanes
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
11 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intralipid with/without Omegaven
Arm Type
Experimental
Arm Description
Lipid infusion with/without marine n-3 fatty acids
Intervention Type
Dietary Supplement
Intervention Name(s)
Intralipid +/- Omegaven
Other Intervention Name(s)
Fresenius Kabi, ATC main group B05B A 02, Intralipid Vnr 42 79 55, Omegaven Vnr 55 25 54
Intervention Description
Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.
Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.
Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil).
Primary Outcome Measure Information:
Title
insulin sensitivity
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
n-3 fatty acid distribution
Time Frame
4 hours
Title
insulin secretion
Time Frame
4 hours
Title
energy metabolism
Time Frame
4 hours
Title
oxidative stress
Time Frame
4 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes defined by clinical criteria and by absence of antibodies to glutamic acid decarboxylase.
HbA1c 5,5 - 8,5 %
Blood pressure ≤ 170 mm Hg systolic and/or ≤ 105 mm Hg diastolic
Exclusion Criteria:
insulin treatment
hypertriglyceridemia (> 2,1 mmol/l TG)
proliferative retinopathy, renal insufficiency (Se-Creatinine > 150 μmol/l)
alcoholism, congestive heart failure or other serious diseases affecting the possibility of the subject to participate
supplement with fish oil or marine n-3 fatty acids during the last 6 months before baseline
Dicumarol treatment
allergy to soya, fish or egg
pregnancy or lactation
smoking
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Valdemar Grill, M.D.
Organizational Affiliation
St. Olavs Hospital, NTNU
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Medicine, Division of Endocrinology, St. Olavs Hospital
City
Trondheim
ZIP/Postal Code
N-7006
Country
Norway
12. IPD Sharing Statement
Citations:
PubMed Identifier
19716144
Citation
Mostad IL, Bjerve KS, Basu S, Sutton P, Frayn KN, Grill V. Addition of n-3 fatty acids to a 4-hour lipid infusion does not affect insulin sensitivity, insulin secretion, or markers of oxidative stress in subjects with type 2 diabetes mellitus. Metabolism. 2009 Dec;58(12):1753-61. doi: 10.1016/j.metabol.2009.06.003. Epub 2009 Aug 27.
Results Reference
result
Learn more about this trial
n-3 Fatty Acid Infusion and Type 2 Diabetes
We'll reach out to this number within 24 hrs